Hear our CEO and Founder Mireille Kamariza, Ph.D. talk about her story, and how DMN-Tre could increase the speed, accuracy, and availability of tuberculosis treatment.
This new collaboration with the R2D2 TB Network seeks to facilitate further development of DMN-Tre as a next-generation drug susceptibility test reagent by clinically evaluating it in diverse and relevant study sites across the globe.
OliLux Biosciences will expand its research and clinical operations to develop diagnostic and treatment monitoring tools for the rapid detection and management of tuberculosis in resource-limited settings.
The Stanford.Berkeley.UCSF Next Generation Faculty Symposium is a platform designed to highlight the work of exceptional early-career scientists in the broad field of quantitative biological and biomedical sciences, with a track record of research productivity and demonstrated contributions to enhancing diversity, equity, and inclusion in STEM.
Co-founder & CEO Mireille Kamariza was one of C&EN's Talented 12 young rising stars who are using chemical know-how to change the world.
By setting up MediLux Biosciences Pte. Ltd. in Singapore, OliLux affirms our global commitment to fight TB by expanding our footprint to Southeast Asia.
StartX is an educational non-profit that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence.
Cardinal Ventures is a startup accelerator on the Stanford campus run by students, for students.
"We’ve come up with a TB test that’s cheaper, quicker and more accurate" written by our very own Bavesh Kana, PhD.
"Glowing Molecule Can Reveal Live Tuberculosis Bacteria" written by Meghan Rosen.
Kamariza, M., et al., "Rapid detection of Mycobacterium tuberculosis in sputum with a solvatochromic trehalose probe." Science Translational Medicine. Vol. 10, Issue 430, eaam6310.
"Simple test could quickly detect tuberculosis in developing countries" written by Robert F. Service.